Search

everythinglearnresearchcommunity

for

Search:↓

Hair regrowth in alopecia universalis may be possible by altering immune cells.

RAGE is a potential target for melanoma treatment, but its effectiveness is uncertain due to variable expression levels.

Some patients developed hair loss after islet cell transplant possibly due to their immune-suppressing medications.

The document explains how the immune system reacts to organ transplants and the treatments used to prevent rejection.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

CD8+ T cells drive alopecia areata, while regulatory T cells are protective.

Tph cells are linked to the severity of systemic lupus erythematosus.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

A woman with lupus had blood cell destruction, treated successfully with medication.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

Tislelizumab can cause cutaneous lupus erythematosus.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

A woman had a rare skin condition with recurring painful nodules that heal in 6 weeks, often without needing treatment.

Anti-CD19 therapy may help treat SLE and NMOSD.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Belimumab may cause hair loss in lupus patients.

Belimumab effectively controls SLE disease activity and reduces steroid use.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.

CD4+ lymphocytopenia can occur in patients with systemic lupus erythematosus.

Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.

SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.